

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILINO	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/677,977	10/02/2003		Jack Nguyen	25840-501	9061
7590 04/11/2006				EXAMINER	
Ivor Elrifi, Esq.				WESSENDORF, TERESA D	
Mintz, Levin, Cohn, Ferris,					
Glovsky and Popeo, P.C.				ART UNIT	PAPER NUMBER
One Financial Center				1639	
Boston, MA 02111				DATE MAILED: 04/11/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/677,977	NGUYEN ET AL.
Office Action Summary	Examiner	Art Unit
	T. D. Wessendorf	1639
The MAILING DATE of this communication apperiod for Reply	opears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION .136(a). In no event, however, may a reply be tined will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. nety filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
<ul> <li>1) ⊠ Responsive to communication(s) filed on 01 / 2a) ☐ This action is FINAL.</li> <li>2b) ☒ This 3) ☐ Since this application is in condition for allowed closed in accordance with the practice under</li> </ul>	is action is non-final. ( Meshiotic ance except for formal matters, pro	secution as to the merits is
Disposition of Claims	<u>.</u>	
<ul> <li>4)</li></ul>	awn from consideration.	ection requirement.
Application Papers		
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) acceptant may not request that any objection to the Replacement drawing sheet(s) including the correction of the correction of the oath or declaration is objected to by the Examination is objected to be a control in the Examination is objected to be	ccepted or b) objected to by the section is required if the drawing(s) is objection is required if the drawing(s) is objection is required.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents.</li> <li>2. Certified copies of the priority documents.</li> <li>3. Copies of the certified copies of the principle application from the International Bureat * See the attached detailed Office action for a list.</li> </ul>	nts have been received.  Ints have been received in Application in the second in the second in the second interest in the second interest in the second interest in the second interest interest interest in the second interest i	on No ed in this National Stage
Attachment(s)		
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date</li> </ol>	4) Interview Summary Paper No(s)/Mail D  5) Notice of Informal F  6) Other:	

Art Unit: 1639

## DETAILED ACTION

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-7, 9, 11-16, 45-48 and 50-52 drawn to a method of identifying a mammalian protease mutein wherein the target is as recited therein.
- II. Claims 53-54, 56-58, drawn to a method of identifying a protease mutein comprising the recited protease therein comprising steps (a)-(f).
- III. Claims 59-62, drawn to a method of identifying a human protease mutein employing the recited target and protease therein.
- IV. Claims 63-66, drawn to drawn to a method of identifying a human protease mutein employing the recited target and different species of proteases therein.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

Application/Control Number: 10/677,977

Art Unit: 1639

In the instant case the different inventions are drawn to different methods comprising different components and/or method steps. For example, the method of Group I relates to screening employing the different recited targets therein using any type of protease. Group II recites some species of the target and protease and includes additional steps.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and the search required for Group I is not required for Groups II-IV, specifically the literature searches, restriction for examination purposes as indicated is proper.

Claims 1, 7, 8, 12, 53, 59 and 63 are generic to a plurality of disclosed patentably distinct species comprising protease and target. Applicants are to elect a <u>single</u> species of a <u>target</u>, for example, tumor necrosis factor (see e.g., claim 63) and a <u>single species of protease</u> e.g., granzyme A or B or M or cathepsin as recited in e.g., claim 7.

Each of the species in each of the target and protease differs in structure, function, effects and mode of action. A prior art reference anticipating one species would not render obvious the other species.

Application/Control Number: 10/677,977

Art Unit: 1639

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of a target and a protease, for examination purposes, even though this requirement is traversed.

Applicant(s) is/are advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant(s) will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant(s) must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the

inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. D. Wessendorf whose telephone number is(571)272-0812. The examiner can normally be reached on Flexitime.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571)272-0811. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/677,977

Art Unit: 1639

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

T. D. Wessendorf Primary Examiner Art Unit 1639 Page 6

tdw April 1, 2006